公开(公告)号：US5364635A

公开(公告)日：1994-11-15

申请号：US97057

申请日：1993-07-27

Applicant: Helmut Fricke ,  Thomas Moest ,  Ernst Flaig

Inventor： Helmut Fricke ,  Thomas Moest ,  Ernst Flaig

IPC: A61K9/16 ,  A61K31/275

CPC classification number: A61K9/1688 ,  A61K31/275

Abstract: A solid drug form containing not less than 90% by weight verapamil is produced by granulating at from 30.degree. to 55.degree. C. with a little water, drying and, where appropriate, conventional tableting or by pelleting, in which case the granules obtained as described are, after cooling, moistened once again and compacted in a granulating mixer at from 30.degree. to 55.degree. C. and are dried.

Abstract translation: 含有不少于90％（重量）维拉帕米的固体药物通过用少量水在30-55℃进行造粒，干燥和适当时通过造粒或通过造粒将其制成为 冷却后再次润湿，在30〜55℃的造粒混合机中压实，并干燥。

公开(公告)号：US4826043A

公开(公告)日：1989-05-02

申请号：US66996

申请日：1987-06-29

Applicant: Ludwig Matz ,  Thomas Moest

Inventor： Ludwig Matz ,  Thomas Moest

IPC: G01F11/24 ,  B65D83/04 ,  G01F11/26

CPC classification number: B65D83/0409 ,  B65D83/04 ,  B65D2583/0495

Abstract: In an apparatus for removing portions of identical materials (4) in the form of pieces by means of a sliding part which is encased in a dispensing container and operated from the outside and whose dispensing sector (5) is filled from inside the container and can be emptied outward, the sliding part is in the form of a tube section (1) which has one or more dispensing sectors (5) and is fed through an outer shell (3) and a stripper (2) located adjacent to the ejection orifice (9) and assigned to the dispensing sectors (5).

Abstract translation: 在用于通过滑动部分去除部分相同材料（4）的装置中，所述滑动部分被包装在分配容器中并从外部操作，并且其分配部分（5）从容器内部填充并且可以 被向外排空，滑动部分是具有一个或多个分配扇区（5）的管段（1）的形式，并且通过外部壳体（3）和位于喷射口附近的剥离器（2） （9）并分配给分配扇区（5）。

公开(公告)号：US4797287A

公开(公告)日：1989-01-10

申请号：US45194

申请日：1987-04-30

Applicant: Claus H. Pich ,  Thomas Moest

Inventor： Claus H. Pich ,  Thomas Moest

IPC: A61J3/10 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  B30B11/00 ,  B30B11/08 ,  B30B15/00

CPC classification number: B30B15/0094 ,  A61J3/10 ,  A61K9/2072 ,  A61K9/2866 ,  B30B11/005 ,  B30B11/08

Abstract: Cylindrical microtablets which have a convex upper face and a convex lower face and whose cylinder diameter and height independently of one another are each from 1.0 to 2.5 mm and the ratio of the said diameter to said height is from 1:0.5 to 1:1.5, and a process for their preparation.

Abstract translation: 具有凸上表面和凸下表面以及圆柱体直径和高度彼此独立的圆柱形微片分别为1.0至2.5mm，所述直径与所述高度之比为1:0.5至1:1.5， 及其准备过程。

公开(公告)号：US08999394B2

公开(公告)日：2015-04-07

申请号：US12806942

申请日：2010-08-24

Applicant: Thomas Moest ,  Manfred Kurfürst ,  Walter Doleschal

Inventor： Thomas Moest ,  Manfred Kurfürst ,  Walter Doleschal

IPC: A61K9/16 ,  C12N9/94 ,  A61K9/14 ,  A61K9/50 ,  A61K38/46 ,  A61K38/47 ,  A61K38/48

CPC classification number: A61K9/14 ,  A61K9/5031 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5089 ,  A61K38/465 ,  A61K38/47 ,  A61K38/48 ,  A61K2300/00

Abstract: In order to prevent impairment of the pharmacological effect of pancreatine through added auxiliary substances or binding agents a pancreatine pellet consists exclusively of pancreatine.

Abstract translation: 为了防止胰腺通过添加的辅助物质或粘合剂的药理作用受损，胰腺丸粒仅由胰腺组成。

公开(公告)号：US08691282B2

公开(公告)日：2014-04-08

申请号：US13368415

申请日：2012-02-08

Applicant: Thomas Moest ,  Walter Doleschal ,  Manfred Kurfürst

Inventor： Thomas Moest ,  Walter Doleschal ,  Manfred Kurfürst

IPC: A61K9/16 ,  A61K9/50

CPC classification number: A61K9/1688 ,  A61K9/5021 ,  A61K9/5073 ,  A61K9/5089 ,  A61K35/39 ,  A61K38/00 ,  A61K38/48 ,  C12N9/94

Abstract: In order to avoid compromising the pharmacological effect of pancreatin caused by the addition of auxiliary materials or binding agents, a pancreatin pellet having a 100% pancreatin content consists exclusively of pancreatin with a residual moisture content of less than 3% by weight, preferably less than 1% by weight or less than 0.5% by weight.

Abstract translation: 为了避免由于添加辅助材料或粘合剂而导致的胰酶的药理作用的损害，具有100％胰酶含量的胰酶颗粒仅由胰酶组成，残留水分含量小于3重量％，优选小于 1重量％或小于0.5重量％。

公开(公告)号：US20110268844A1

公开(公告)日：2011-11-03

申请号：US13060712

申请日：2009-08-27

Applicant: Christian Rämsch ,  Thomas Schräder ,  Thomas Moest ,  Manfred Kurfürst

Inventor： Christian Rämsch ,  Thomas Schräder ,  Thomas Moest ,  Manfred Kurfürst

IPC: C12N9/00 ,  A23L1/305 ,  A23L1/28

CPC classification number: A61L2/0011 ,  A61K38/00 ,  C12N9/94

Abstract: The invention relates to a method for reducing the viral and microbial content of biological extracts which contain solids. It is provided that the method comprises the steps (a) provision of the biological extract which contains solids, comprising a biologically active substance, selected from enzymes, proteins and peptides, or a mixture of such substances; and (b) subjecting the biological extract provided in step (a) to a high-pressure treatment; wherein the biological activity of the biological extract which contains solids after the high-pressure treatment is at least 50% of the biological activity of the biological extract which contains solids before the high-pressure treatment.

Abstract translation: 本发明涉及一种减少含有固体的生物提取物的病毒和微生物含量的方法。 提供的方法包括步骤（a）提供含有选自酶，蛋白质和肽的生物活性物质或这些物质的混合物的固体的生物提取物; 和（b）对步骤（a）中提供的生物提取物进行高压处理; 其中在高压处理后含有固体的生物提取物的生物活性是在高压处理前含有固体的生物提取物的生物活性的至少50％。

公开(公告)号：US20090233344A1

公开(公告)日：2009-09-17

申请号：US12403697

申请日：2009-03-13

Applicant: MANFRED KURFURST ,  Christian Ramsch ,  Thomas Schrader ,  Thomas Moest

Inventor： MANFRED KURFURST ,  Christian Ramsch ,  Thomas Schrader ,  Thomas Moest

IPC: C12N9/94

CPC classification number: C12N9/94 ,  A61L2/0023

Abstract: The invention relates to a method for producing pancreatin with reduced viral and microbial contamination, comprising the steps of (a) providing the pancreatin in solid form with a residual moisture of 0.5 weight % or less, down to almost zero, based on the pancreatin provided; (b) subjecting the pancreatin provided in step (a) to a heat treatment at a temperature of 84° C., preferably 80° C. and below; wherein, the biological activity of the pancreatin obtained in step (b) corresponds to at least 50% of the biological activity of the pancreatin provided in step (a); and the viral infectiousness of the pancreatin obtained in step (b) has been reduced by a factor of more than 1 log10 in comparison with the viral infectiousness of the pancreatin provided in step (a), as well as a pancreatin produced according to this method and its use for producing a medicine or a nutritional supplement.

Abstract translation: 本发明涉及一种生产具有减少的病毒和微生物污染的胰酶的方法，其包括以下步骤：（a）基于所提供的胰酶，提供固体形式的胰酶，残留水分为0.5重量％或更少，至少几乎为零 ; （b）使步骤（a）中提供的胰酶在84℃，优选80℃及以下的温度下进行热处理; 其中，步骤（b）中获得的胰酶的生物活性对应于步骤（a）中提供的胰酶的生物活性的至少50％。 与步骤（a）中提供的胰酶的病毒感染性相比，步骤（b）中获得的胰酶的病毒感染性降低了大于1log10的因子，以及根据该方法制备的胰酶 及其用于生产药物或营养补充剂的用途。

公开(公告)号：US5270055A

公开(公告)日：1993-12-14

申请号：US426018

申请日：1989-10-24

Applicant: Thomas Moest

Inventor： Thomas Moest

IPC: A61K9/22 ,  A61K9/50 ,  A61K9/58 ,  A61K9/62 ,  A61K9/24 ,  A61K9/36 ,  A61K9/42

CPC classification number: A61K9/5073

Abstract: A solid pharmaceutical sustained-release form, consisting of a core containing the active compound as well as conventional pharmaceutical auxiliaries, a coat which delays the release of the active compound and an antiadhesive outer layer, wherein the coat consists of a physiologically acceptable fat-like or wax-like hydrophobic layer which melts in the range from 30.degree. to 120.degree. C. and contains, in addition to conventional pharmaceutical auxiliaries, one or more water-insoluble polymers, and a process for its preparation.

Abstract translation: 固体药物缓释形式，由含有活性化合物的核心以及常规药物助剂组成，延长活性化合物释放的涂层和抗粘附外层，其中该涂层由生理上可接受的脂肪样 或蜡状疏水层，其在30℃至120℃的范围内熔融，并且除常规药物助剂外还含有一种或多种水不溶性聚合物及其制备方法。

公开(公告)号：US4632843A

公开(公告)日：1986-12-30

申请号：US581714

申请日：1984-02-21

Applicant: Claus H. Pich ,  Thomas Moest

Inventor： Claus H. Pich ,  Thomas Moest

IPC: C07C67/055 ,  A61K9/16 ,  A61K9/54 ,  A61K31/26 ,  A61K33/06 ,  A61K33/14 ,  C01D3/22 ,  C01F5/40 ,  C01G49/14 ,  C07C51/00 ,  C07C51/43 ,  C07C67/00 ,  C30B7/08 ,  C30B29/60 ,  A61K9/48

CPC classification number: A61K9/1688 ,  C30B7/00 ,  Y10S514/951 ,  Y10S514/963 ,  Y10S514/965

Abstract: A process for the preparation of solid pharmaceutical products, wherein, in a first step, spherical single crystals of a pharmaceutical active compound or assistant are prepared by agitating a saturated aqueous, organic or organic-aqueous solution in high speed stirred crystallizers or draft-tube crystallizers at 50-500 revolutions per minute and seeding the solution with finely ground seed crystals of particle size less than 100 .mu.m, while ensuring that at the time of addition of the seed crystals and during the growth thereof the solution is at all times only minimally supersaturated, this being achieved by slow cooling at a rate of not more than 50 K/h or corresponding slow evaporation of the solution, and in a second step the resulting spherical single crystals with diameters of 0.1-3 mm, preferably 0.5-2 mm, are separated from the solution, dried at 40.degree.-200.degree. C., compounded, where appropriate, with suitable pharmaceutical assistants or, if the single crystals serve as assistants, with suitable pharmaceutical active compounds, and then converted to solid pharmaceutical products by coating, tableting or filling into hard gelatin capsules.

Abstract translation: 一种制备固体药物产品的方法，其中在第一步中，通过在高速搅拌结晶器或引流管中搅拌饱和水溶液，有机或有机水溶液来制备药物活性化合物或助剂的球形单晶 结晶器以50-500转/分钟的速度接种，并用晶粒尺寸小于100微米的精细研磨晶种接种溶液，同时确保在加入晶种时，在其生长过程中溶液始终处于 最低限度过饱和，这是通过以不超过50K / h的速度缓慢冷却或相应的溶液缓慢蒸发来实现的，而在第二步中，得到的直径为0.1-3mm，优选为0.5-2的球形单晶 mm，与溶液分离，在40℃-200℃下干燥，在合适的情况下，用合适的药物助剂混合，或者如果单晶作为助剂 与合适的药物活性化合物混合，然后通过涂布，压片或填充到硬明胶胶囊中转化为固体药物产品。

公开(公告)号：US4340614A

公开(公告)日：1982-07-20

申请号：US267870

申请日：1981-05-28

Applicant: Claus H. Pich ,  Thomas Moest

Inventor： Claus H. Pich ,  Thomas Moest

IPC: A23L27/23 ,  A23L27/40 ,  A23L1/237

CPC classification number: A23L27/45 ,  A23L27/235

Abstract: A stringently sodium-restricted dietetic salt consisting of a mixture of from 60 to 85% by weight of potassium chloride, from 10 to 30% by weight of potassium adipate, from 2 to 5% by weight of potassium tartrate, from 0.5 to 2% by weight of potassium glutamate, from 0.5 to 2% by weight of adipic acid and a total of from 0.004 to 0.06% by weight of potassium inosate and/or potassium guanylate, and the preparation of the salt in a fluidized bed apparatus.

Abstract translation: 严格的钠限制饮食盐，其由60至85重量％的氯化钾，10至30重量％的己二酸钾，2至5重量％的酒石酸钾，0.5至2重量％ 的谷氨酸钾，0.5至2重量％的己二酸和总计0.004至0.06重量％的氢氧化钾和/或鸟苷酸钾，以及在流化床装置中制备该盐。